Randomised Immunogenicity Trial Comparing 2019-2020 Recombinant and Egg-based Influenza Vaccines Among Frequently Vaccinated Healthcare Personnel in Israel.

Details

• Alternative Title:
  International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 2024, v. 149: Randomised Immunogenicity Trial Comparing 2019-2020 Recombinant and Egg-based Influenza Vaccines Among Frequently Vaccinated Healthcare Personnel in Israel.
• Journal Article:
  International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
• Personal Author:
  Fowlkes, Ashley L. ; Peretz, Alon ; Greenberg, David ; Hirsch, Avital ; Martin, Emily T. ; Levine, Min Z. ; Edwards, Laura ; Radke, Sarah ; Lauring, Adam S. ; Ferdinands, Jill M. ; Zhang, Chao ; Yoo, Young M. ; Dreiher, Jacob ; Newes-Adeyi, Gabriella ; Azziz-Baumgartner, Eduardo ; Fry, Alicia M. ; Monto, Arnold S. ; Balicer, Ran ; Thompson, Mark G. ; Katz, Mark A.
• Description:
  Trivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016 to 2019. We conducted a randomised immunogenicity trial of quadrivalent recombinant influenza vaccine (RIV4) and standard-dose inactivated influenza vaccine (IIV4) among frequently and infrequently vaccinated previous cohort participants.
  
  From October 2019 to January 2020, we enrolled and randomly allocated HCP from two Israeli hospitals to receive IIV4 or RIV4. Hemagglutination inhibition (HAI) antibody titres against 2019-2020 vaccine reference influenza viruses were compared between vaccine groups using geometric mean titre (GMT) ratios from sera collected one-month post-vaccination and by frequency of vaccination in the past 5 years (>2 vs ≤2).
  
  Among 415 HCP, the GMT ratio comparing RIV4 to IIV4 was 2.0 (95% confidence interval CI 1.7-2.7) for A(H1N1)pdm09, 1.6 (95% CI: 1.3-1.9) for A(H3N2), 1.8 (95% CI: 1.4-2.2) for B(Yamagata), and 1.1 (95% CI: 0.9-1.4) for B(Victoria). Similarly, RIV4 elicited higher HAI titres than IIV4 against all 2019-2020 vaccine reference viruses except B(Victoria) among infrequently and frequently vaccinated HCP (lower bound of GMT ratio 95% CIs ≥1.0).
  
  RIV4 had improved immunogenicity for influenza vaccine strains among both infrequent and frequent vaccinees compared to standard-dose IIV4.
  
  NCT04523324.
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Influenza Vaccines
  • Health Personnel
  • Female
  • Adult
  • Influenza, Human
  • Male
  • Antibodies, Viral
  • Middle Aged
  • Vaccines, Synthetic
  More +
• Keywords:
  • Influenza vaccine
  • Recombinant
  • Immunogenicity
  • Healthcare personnel
  • Flublok
• Source:
  International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases, 2024, v. 149
• DOI:
  https://doi.org/10.1016/j.ijid.2024.107260
• ISSN:
  1201-9712 ; 1878-3511
• Pubmed ID:
  39395753
• Pubmed Central ID:
  PMC11883642
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  Israel
• Pages in Document:
  107260 (21 pdf pages)
• Volume:
  149
• Download URL:
  https://stacks.cdc.gov/view/cdc/261987/cdc_261987_DS1.pdf
• File Type:
  [PDF - 811.33 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:2675c1e0dbd3b4f68ef06e6f7593d200d396c1e0aacbd5f22a43984d7c598e6434e526a18cff77e494a3f0a38c3de0816e0362d0a68243e520535667947650c2